Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US Biotech Arteriocyte has completed enrollment for its phase I clinical trial of ACY001, its lead cellular therapy product designed to target cardiovascular disease.
Subscribe to our email newsletter
Arteriocyte’s trial is among the first to target heart disease with stem cell treatments
The study is evaluating the safety of ACY001, an adult stem cell therapy harvested from bone marrow to treat chronic ischemia, a serious form of heart disease.
The study is being conducted at University Hospitals Case Medical Center and will evaluate the safety of infusing adult derived selected stem cells into the coronary arteries of patients.
“The trial’s novel therapeutic approach provides an important opportunity to assess stem cell therapy in the no-option chronic ischemia patient, typically patients who have failed to benefit from prior surgical interventions,” added Phil Cola, vice president of Research and Technology at University Hospitals Case Medical Center.
A clinical update on the trial will be presented at the Transcatheter Cardiovascular Therapies conference in on October 27, 2006.